202 related articles for article (PubMed ID: 28881627)
1. Structural basis of a novel heterodimeric Fc for bispecific antibody production.
Wei H; Cai H; Jin Y; Wang P; Zhang Q; Lin Y; Wang W; Cheng J; Zeng N; Xu T; Zhou A
Oncotarget; 2017 Aug; 8(31):51037-51049. PubMed ID: 28881627
[TBL] [Abstract][Full Text] [Related]
2. Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
Kuglstatter A; Stihle M; Neumann C; Müller C; Schaefer W; Klein C; Benz J;
Protein Eng Des Sel; 2017 Sep; 30(9):649-656. PubMed ID: 28985438
[TBL] [Abstract][Full Text] [Related]
3. Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction.
Elliott JM; Ultsch M; Lee J; Tong R; Takeda K; Spiess C; Eigenbrot C; Scheer JM
J Mol Biol; 2014 May; 426(9):1947-57. PubMed ID: 24576605
[TBL] [Abstract][Full Text] [Related]
4. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.
Liu Z; Leng EC; Gunasekaran K; Pentony M; Shen M; Howard M; Stoops J; Manchulenko K; Razinkov V; Liu H; Fanslow W; Hu Z; Sun N; Hasegawa H; Clark R; Foltz IN; Yan W
J Biol Chem; 2015 Mar; 290(12):7535-62. PubMed ID: 25583986
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation.
Choi HJ; Seok SH; Kim YJ; Seo MD; Kim YS
Mol Immunol; 2015 Jun; 65(2):377-83. PubMed ID: 25743157
[TBL] [Abstract][Full Text] [Related]
6. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.
Moore GL; Bernett MJ; Rashid R; Pong EW; Nguyen DT; Jacinto J; Eivazi A; Nisthal A; Diaz JE; Chu SY; Muchhal US; Desjarlais JR
Methods; 2019 Feb; 154():38-50. PubMed ID: 30366098
[TBL] [Abstract][Full Text] [Related]
7. Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening.
Choi HJ; Kim YJ; Choi DK; Kim YS
PLoS One; 2015; 10(12):e0145349. PubMed ID: 26675656
[TBL] [Abstract][Full Text] [Related]
8. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.
Gunasekaran K; Pentony M; Shen M; Garrett L; Forte C; Woodward A; Ng SB; Born T; Retter M; Manchulenko K; Sweet H; Foltz IN; Wittekind M; Yan W
J Biol Chem; 2010 Jun; 285(25):19637-46. PubMed ID: 20400508
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins.
Ha JH; Kim JE; Kim YS
Front Immunol; 2016; 7():394. PubMed ID: 27766096
[TBL] [Abstract][Full Text] [Related]
10. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.
Xu Y; Lee J; Tran C; Heibeck TH; Wang WD; Yang J; Stafford RL; Steiner AR; Sato AK; Hallam TJ; Yin G
MAbs; 2015; 7(1):231-42. PubMed ID: 25427258
[TBL] [Abstract][Full Text] [Related]
11. Structural and Functional Characterization of a Hole-Hole Homodimer Variant in a "Knob-Into-Hole" Bispecific Antibody.
Zhang HM; Li C; Lei M; Lundin V; Lee HY; Ninonuevo M; Lin K; Han G; Sandoval W; Lei D; Ren G; Zhang J; Liu H
Anal Chem; 2017 Dec; 89(24):13494-13501. PubMed ID: 29129068
[TBL] [Abstract][Full Text] [Related]
12. A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species.
Stutz C; Blein S
J Biol Chem; 2020 Jul; 295(28):9392-9408. PubMed ID: 32404368
[TBL] [Abstract][Full Text] [Related]
13. A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line.
Yu J; Wang X; Xu T; Jin Q; Duan J; Wu J; Wu H; Xu T; Ye S
J Biol Chem; 2017 Oct; 292(43):17885-17896. PubMed ID: 28878018
[TBL] [Abstract][Full Text] [Related]
14. Effect of allotypic variation of human IgG1 on the thermal stability of disulfide-linked knobs-into-holes mutants of the Fc for stable bispecific antibody design.
Akiba H; Satoh R; Nagata S; Tsumoto K
Antib Ther; 2019 Jul; 2(3):65-69. PubMed ID: 33928224
[TBL] [Abstract][Full Text] [Related]
15. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
[TBL] [Abstract][Full Text] [Related]
17. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.
Von Kreudenstein TS; Escobar-Carbrera E; Lario PI; D'Angelo I; Brault K; Kelly J; Durocher Y; Baardsnes J; Woods RJ; Xie MH; Girod PA; Suits MD; Boulanger MJ; Poon DK; Ng GY; Dixit SB
MAbs; 2013; 5(5):646-54. PubMed ID: 23924797
[TBL] [Abstract][Full Text] [Related]
18. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
[TBL] [Abstract][Full Text] [Related]
19. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
20. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.
Liu H; Saxena A; Sidhu SS; Wu D
Front Immunol; 2017; 8():38. PubMed ID: 28184223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
